SUZHOU, China, Oct. 25, 2024 /PRNewswire/ -- Recently, NeoMab Biotechnology (Suzhou) Co., Ltd. (referred to as "NeoMab") launched the innovative NeoMab-IgG Ease model, based on its next-generation fully human antibody transgenic mouse model--NeoMab. This advancement marks another significant breakthrough for NeoMab in the field of antibody drug development. The NeoMab-IgG Ease model simplifies the antibody drug development process significantly with its unique "milestone-free, live mouse provision" approach, making commercial collaboration more efficient and convenient.

What are the Features of NeoMab?

NeoMab mice utilize human V(D)J gene-encoded antibodies, exhibiting gene usage frequency and sequence diversity similar to humans, making them suitable for fully human antibody development. Their competent immune system is capable of efficiently performing antigen presentation, antibody production, and affinity maturation. The unique BALB/c genetic background and antigen presentation system enhance the ability to present antigens, with serum titers reaching 10^5 to 10^6 after 3-4 rounds of immunizations, promoting the generation of high-affinity antibodies. SPR testing shows that the antibody affinities of NeoMab mice range from 10^-8 to 10^-10, meeting various needs for fully humanized antibody development.

How is NeoMab's Collaboration Model Innovative?

NeoMab is committed to providing convenient one-stop services for its clients. The NeoMab-IgG Ease model employs a "milestone-free, live mouse provision" business model, eliminating lengthy negotiations and milestone payment processes. Clients can directly obtain live mice for immunization, allowing for the rapid development of fully human therapeutic antibodies. This streamlined collaboration enhances flexibility and optimizes the complex payment and agreement processes typical of traditional business models.

What are the Advantages of Partnering with NeoMab?

Through the NeoMab platform, clients can access the NeoMab models and have the opportunity to obtain a variety of fully human building blocks such as IgG, ScFv, and Fab, catering to the development of various drug types and cell therapies, including ADCs, AOCs, and mono/bi/multispecific antibodies and nanobodies. NeoMab provides a comprehensive range of services from target validation to IND filing, ensuring a seamless experimental process. By integrating antibody screening with in vivo experimental animal models, NeoMab significantly accelerates the in vivo animal study process and eliminates the costs associated with humanization, helping clients shorten drug development timelines by up to 1.5 years. Partners have expressed their recognition and affirmation of NeoMab's services in accelerating the research and development process.

About NeoMab

NeoMab Biotechnology (Suzhou) Co., Ltd., a wholly-owned subsidiary of GemPharmatech, is based in the Suzhou Biomedicine Industry Park (BioBAY). The company specializes in efficient antibody drug discovery services and aims to be a trusted partner for clients. With an experienced team and advanced laboratories, NeoMab provides comprehensive services, including target validation, antibody production, screening, and preclinical research. It also offers flexible collaboration models, such as mouse licensing, fully human antibody development, and molecule licensing.

For more information, please contact BD at BD@neomab-bio.com.

Photo -
Photo -
Photo -
Photo -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/neomab-fully-human-antibody-discovery-platform-a-new-flexible-mouse-purchase-model-leading-a-new-trend-in-antibody-drug-development-302287448.html

Images

Tags

More Like This

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform